ZYVOX (linezolid) by Pfizer is 12. Approved for pneumonia, gram-positive bacterial infections, tuberculosis and 11 more indications. First approved in 2000.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
ZYVOX (linezolid) is an oxazolidinone antibiotic that inhibits bacterial protein synthesis and is used to treat serious gram-positive infections including vancomycin-resistant enterococci, MRSA, and various pneumonias. It is available in both oral and intravenous formulations with 100% oral bioavailability, enabling flexible dosing without adjustment between routes. The drug has a broad spectrum of indications spanning nosocomial, community-acquired, and specialized infections including tuberculosis and prosthetic joint infections.
As a mature product approaching loss of exclusivity with minimal Part D claims, ZYVOX teams are likely focused on cost optimization and defending generic erosion rather than growth initiatives.
12.1 Mechanism of Action Linezolid is an antibacterial drug [ see ] . 12.2 Pharmacodynamics In a randomized, positive- and placebo-controlled crossover thorough QT study, 40 healthy subjects were administered a single linezolid 600 mg dose via a 1 hour intravenous infusion, a single linezolid 1,200…
Worked on ZYVOX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Oxazolidinone Antibacterial
Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis
Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
Model-informed Precision Dosing for Linezolid
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ZYVOX offers limited growth prospects given its LOE-approaching status and minimal linked job openings; career trajectories are typically short-term focused on market defense and transition planning. Professionals joining the team should expect roles emphasizing cost containment, generic education, and niche positioning rather than expansion or innovation.